Abstract:The COVID-19 pandemic has caused more than 5 million of deaths around the world in less than two years, and it is still unfolding (https://coronavirus.jhu.edu/map.html). Because of the high complexity of COVID-19 pathogenesis, it is of great interest to understand the host responses to SARS-CoV-2 infection at protein level. These responses include two layers, one of which is the immune responses to viral proteins, especially the antibody responses. Another is the change of the human protein level upon SARS-CoV-2 infection. To profile the antibody responses, a serial of studies has been carried out. For example, Tao et al., developed a SARS-CoV-2 proteome microarray and a peptide microarray that fully covers the Spike protein.1Li Y Xu Z Lei Q Lai DY Hou H Jiang HW et al.Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.Cell Rep. 2021; 36109391Summary Full Text Full Text PDF Scopus (13) Google Scholar, 2Jiang HW Li Y Zhang HN Wang W Yang X Qi H et al.SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.Nat Commun. 2020; 11: 3581Crossref PubMed Scopus (124) Google Scholar, 3Li Y Ma ML Lei Q Wang F Hong W Lai DY et al.Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.Cell Rep. 2021; 34108915Summary Full Text Full Text PDF Scopus (47) Google Scholar Based on these arrays, ∼2,000 COVID-19 sera of varied severity were analyzed. Bead-based systems were also applied to determine the SARS-CoV-2 specific antibody responses.4Becker M Strengert M Junker D Kaiser PD Kerrinnes T Traenkle B et al.Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.Nat Commun. 2021; 12: 1152Crossref PubMed Scopus (27) Google Scholar Alternatively, Yu et al., developed a peptide microarray that fully covers all the SARS-CoV-2 proteins and allows us to construct an overall picture of epitopes for SARS-CoV-2 antibodies COVID-19 infection.5Wang H Wu X Zhang X Hou X Liang T Wang D et al.SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution.ACS Cent Sci. 2020; 6: 2238-2249Crossref PubMed Scopus (68) Google Scholar To monitor the SARS-CoV-2 specific human protein change, several proteomics bases studies have been performed. Guo et al.,6Shen B Yi X Sun Y Bi X Du J Zhang C et al.Proteomic and metabolomic characterization of COVID-19.Patient Sera. Cell. 2020; 182 (e15): 59-72Scopus (571) Google Scholar accomplished a proteomic analysis of 144 autopsy samples from seven organs in 19 COVID-19 patients. In comparison to the controls, they found that more than 5,000 proteins were altered in the COVID-19 patients. By applying O-link technology, Filbin et al., (from the same group of this study) have analyzed COVID-19 samples of severe symptoms.7Filbin MR Mehta A Schneider AM Kays KR Guess JR Gentili M et al.Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions.Cell Rep Med. 2021; 2100287Google Scholar In this paper of EBioMedicine, Zhong et al capitalized on the O-link technology and quantitatively analyzed the plasma protein profile (∼1,500 proteins) of 50 COVID-19 patients with mild and moderate symptoms.8Zhong W Altay O Arif M Edfors F Doganay L Mardinoglu A et al.Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms.EBioMedicine. 2021; 74103723Summary Full Text Full Text PDF Scopus (6) Google Scholar They found the levels of 200 proteins were significantly higher when diagnosed than that of 14 days after diagnosis, and many of these proteins are related to cytokines and immune responses. In this study, Zhong et al., have made interesting findings. Some are consistent to previous studies while some are new. A few of these findings are worth further exploration. Firstly, upon SARS-CoV-2 infection, the levels of many proteins are increased, while there is no statistical difference among patients of mild, moderate and severe symptoms. This indicate profiles of these proteins are independent of symptoms, which have potential to be used as biomarkers for the diagnosis of COVID-19. Secondly, the authors identified the protein scavenger receptor class B member 2 (SCARB2) as the most significantly elevated protein upon infection. After comprehensive validation, the connection between SCARB2 and COVID-19 may warrant further in-depth functional exploration to reveal the underlying mechanistic role. Thirdly, authors found that many of the older patients, although free of symptom, have a plasma profile similar to that of patients with the active infection even after 14 days of diagnosis. It is well known that COVID-19 is more dangerous to old people. Thus this observation is worth of further study. It is known that old COVID-19 patients usually have high SARS-CoV-2 specific antibody level.2Jiang HW Li Y Zhang HN Wang W Yang X Qi H et al.SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.Nat Commun. 2020; 11: 3581Crossref PubMed Scopus (124) Google Scholar So, is it possible that there are some correlations between high protein level and the high antibody level? The key platform used in this study is the O-link technology. The beauty of O-link resides in its power of quantitative and simultaneous analysis of many proteins, that even of low abundance. However, it has limitations. First, the number of proteins that could be analyzed is still far fewer than mass spectrometry. However, these two technologies could be complementary to each other. Another limitation is the difficulty for pairing of antibodies for each target protein. This could be overcome by a highly efficient epitope mapping technology.9Qi H Ma M Hu C Xu ZW Wu FL Wang N et al.Antibody binding epitope mapping (AbMap) of hundred antibodies in a single run.Mol Cell Proteomics. 2021; 20100059Summary Full Text Full Text PDF Google Scholar The study has its merit that ∼1,500 proteins were quantitatively analyzed. However, the findings lack further independent validation. To strengthen these findings, it is anticipated that some validations will be carried out use an independent assay with an independent cohort of samples. The protein profiles were nicely compared between the two time points. If more longitudinal samples could be analyzed, we could then obtain a more detailed picture of the changes of the protein levels over time. Finally, to combat the COVID-19 pandemic in a more efficient way, it is urgent to generate a comprehensive knowledge map by integrating varies of proteomics data, including the data of this study, from both antibody level and protein level.10Xu Z Li Y Lei Q Huang L Lai DY Guo SJ et al.COVID-ONE-hi: the one-stop database for COVID-19 specific humoral immunity and clinical parameters.Genom Proteom Bioinformat. 2021; Crossref Scopus (2) Google Scholar Commentary was written by H.-W. J and S.-c. T. No disclosure relevant to this topic. We are indebted with our team, and our collaborators on COVID-19 related studies, especially Professor Xionglin Fan from Huazhong University of Science and Technology, and Professor Hongping Wei from Wuhan Institute of Virology, Chinese Academy of Sciences. Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptomsThe study presented here demonstrates the usefulness of “next generation plasma protein profiling” to identify molecular signatures of importance for disease progression and to allow monitoring of disease during recovery from the infection. The results will facilitate further studies to understand the molecular mechanism of the immune-related response of the SARS-CoV-2 virus. Full-Text PDF Open Access

Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes

Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer’s and coronary disease pathways

Plasma Proteomics Elucidated a Protein Signature in COVID-19 Patients with Comorbidities and Early-Diagnosis Biomarkers

Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19

Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity

Proteomic blood profiling in mild, severe and critical COVID-19 patients

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Proteomics Analysis of Serum from COVID-19 Patients

Plasma Proteomics Unveil Novel Immune Signatures and Biomarkers upon SARS-CoV-2 Infection

Cytokine Elevation in Severe COVID-19 From Longitudinal Proteomics Analysis: Comparison With Sepsis

Quantitative Plasma Proteome Profiling of COVID-19 Patients with Mild and Moderate Symptoms

Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Proteomic characteristics of the treatment trajectory of patients with COVID-19

Short Survey on the Protein Modifications in Plasma during SARS-CoV-2 Infection

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients

Plasma markers of COVID-19 severity: a pilot study

Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19

Circulating proteins to predict COVID-19 severity